相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Philip C. Schouten et al.
CLINICAL CANCER RESEARCH (2021)
Twelve years of SAMtools and BCFtools
Petr Danecek et al.
GIGASCIENCE (2021)
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Laura Martin de la Fuente et al.
VIRCHOWS ARCHIV (2020)
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
Anne Montfort et al.
BRITISH JOURNAL OF CANCER (2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R. E. Miller et al.
ANNALS OF ONCOLOGY (2020)
BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
Nora Sahnane et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
Marta L. Pinto et al.
FRONTIERS IN IMMUNOLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Diverse Functions of Macrophages in Different Tumor Microenvironments
Ming Yang et al.
CANCER RESEARCH (2018)
Copy number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre et al.
NATURE GENETICS (2018)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
S. J. L. Mesnage et al.
ANNALS OF ONCOLOGY (2017)
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
George Au-Yeung et al.
CLINICAL CANCER RESEARCH (2017)
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Xia Yuan et al.
GYNECOLOGIC ONCOLOGY (2017)
CD103+tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+T cells associated with prognostic benefit and therapy response in cervical cancer
Fenne L. Komdeur et al.
ONCOIMMUNOLOGY (2017)
MultiQC: summarize analysis results for multiple tools and samples in a single report
Philip Ewels et al.
BIOINFORMATICS (2016)
Homologous recombination deficiency and ovarian cancer
Jonathan A. Ledermann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer
Min Zhang et al.
GYNECOLOGIC ONCOLOGY (2016)
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
J. Kanska et al.
GYNECOLOGIC ONCOLOGY (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy
Philip C. Schouten et al.
CLINICAL CANCER RESEARCH (2015)
Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong et al.
CLINICAL CANCER RESEARCH (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Trimmomatic: a flexible trimmer for Illumina sequence data
Anthony M. Bolger et al.
BIOINFORMATICS (2014)
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
John R. Webb et al.
CLINICAL CANCER RESEARCH (2014)
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
I. Ruscito et al.
EUROPEAN JOURNAL OF CANCER (2014)
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly
Ilari Scheinin et al.
GENOME RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile
Philip C. Schouten et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Dariush Etemadmoghadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
Jessica N. McAlpine et al.
MODERN PATHOLOGY (2012)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
M. A. Vollebergh et al.
ANNALS OF ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma
Martin Poelcher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
Dariush Etemadmoghadam et al.
CLINICAL CANCER RESEARCH (2009)
Dramatic Response to Platinum in a Patient with Cancer with a Germline BRCA2 Mutation
R. Moule et al.
CLINICAL ONCOLOGY (2009)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne et al.
PLOS ONE (2009)
High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications
Kylie L. Gorringe et al.
CLINICAL CANCER RESEARCH (2007)
Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy
Isabelle Bedrosian et al.
CLINICAL CANCER RESEARCH (2007)
Cyclin E in normal and neoplastic cell cycles
HC Hwang et al.
ONCOGENE (2005)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
分享论文
